ReviewImmunotherapy2013
Vaccine strategies for glioblastoma: progress and future directions.
Review in Immunotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis.PloS one · 2014Pooled it
- Next-generation vaccines are showing promise against glioblastoma.Oncotarget · 2024Article
- Therapeutic cell-based vaccines for glioblastoma multiforme.Medical oncology (Northwood, London, England) · 2023Review
- Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.Frontiers in immunology · 2022Article
- Combination immunotherapy strategies for glioblastoma.Journal of neuro-oncology · 2021Review
- High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme.ACS nano · 2019Article
- Tumor treating fields: a new approach to glioblastoma therapy.Journal of neuro-oncology · 2018Review
- Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma.Neuroimmunology and neuroinflammation · 2018Article
- Tumor Vaccines for Malignant Gliomas.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Developing Therapies for Brain Tumors: The Impact of the Johns Hopkins Hunterian Neurosurgical Research Laboratory.Transactions of the American Clinical and Climatological Association · 2017Review
- Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.Science translational medicine · 2016Article
- Peptide vaccines for the treatment of glioblastoma.Journal of neuro-oncology · 2015Review
- Vaccine therapies in malignant glioma.Current neurology and neuroscience reports · 2015Review
- Immunotherapeutic advancements for glioblastoma.Frontiers in oncology · 2015Review
- Brain Tumor Immunotherapy: What have We Learned so Far?Frontiers in oncology · 2015Review
- Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.Protein & cell · 2014Review
- Vaccine therapies for patients with glioblastoma.Journal of neuro-oncology · 2014Review
- Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.Neurosurgery · 2014Review
- PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.Immunotherapy · 2014Review
- Advances in diagnostic and treatment modalities for intracranial tumors.Journal of veterinary internal medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Recent advances in glioblastoma therapy have led to optimism that more effective therapies will improve outcomes. Immunotherapy is a promising approach that has demonstrated the potential to eradicate cancer cells with cellular-level accuracy while minimizing damage to surrounding healthy tissue. Several vaccination strategies have been evaluated for activity against glioblastoma in clinical trials. These include peptide vaccines, polyvalent dendritic cell vaccines, heat shock protein vaccines and adoptive immunotherapy. In this review, we highlight clinical trials representative of each of these approaches and discuss strategies for integrating these therapies into routine patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.